BioSpace News Archive

The contract furniture and furnishing market in Europe is expected to post a CAGR close to 6% during the period 2019-2023, according to the latest market research report by Technavio.

Anixa Biosciences, Inc., a biotechnology company focused on harnessing the body’s immune system to fight cancer, announced that the United States Patent and Trademark Office has issued US Patent No. 10,360,499, a key component of Anixa’s Cchek™ technology for early detection of cancer.

The Medicines Company reported financial results for the second quarter that ended June 30, 2019. Second quarter highlights included significant progress with the clinical development program for inclisiran and the completion of a public offering of common stock.

The global bay leaf market is expected to post a CAGR close to 6% during the period 2019-2023, according to the latest market research report by Technavio.

One of the nation’s most successful life sciences incubators forms internal investment program to provide seed and early-stage funding for its companies

Texans are seeking justice for harm caused by prescription opioid drugs and turned to Austin-based legal software-as-a-service leader DISCO as its ediscovery partner.

Disruptive Autonomous Surgical System Implements oVio’s Revolutionary Imaging Technology

Leadership team of David Southwell, CEO; Gavin MacBeath, PhD, CSO; Henry Rath, CBO and Robert Crane, CFO-

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), today announces that the first patient has been treated in the adjuvant (pre-temozolomide maintenance) trial arm of VAL-083’s Phase 2 study in MGMT-unmethylated glioblastoma multiforme (GBM) being conducted at the University of Texas MD Anderson Cancer Center (MDACC)

As of June 30, 2019, Odonate had $206.9 million in cash, compared to $139.1 million as of December 31, 2018.